Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Social-skills and parental training plus standard treatment versus standard treatment for children with ADHD--the randomised SOSTRA trial.

Storebø OJ, Gluud C, Winkel P, Simonsen E.

PLoS One. 2012;7(6):e37280. doi: 10.1371/journal.pone.0037280. Epub 2012 Jun 20.

2.
3.

Attachment Competences in Children With ADHD During the Social-Skills Training and Attachment (SOSTRA) Randomized Clinical Trial.

Storebø OJ, Skoog M, Rasmussen PD, Winkel P, Gluud C, Pedersen J, Thomsen PH, Simonsen E.

J Atten Disord. 2015 Oct;19(10):865-71. doi: 10.1177/1087054713520220. Epub 2014 Feb 14.

PMID:
24532801
4.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
5.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
6.

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.

PMID:
21488751
7.

A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.

Tsang TW, Kohn MR, Hermens DF, Clarke SD, Clark CR, Efron D, Cranswick N, Lamb C, Williams LM.

Trials. 2011 Mar 13;12:77. doi: 10.1186/1745-6215-12-77.

8.
9.

Social skills training for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.

Storebø OJ, Skoog M, Damm D, Thomsen PH, Simonsen E, Gluud C.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008223. doi: 10.1002/14651858.CD008223.pub2. Review.

PMID:
22161422
10.

Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.

Zwi M, Jones H, Thorgaard C, York A, Dennis JA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003018. doi: 10.1002/14651858.CD003018.pub3. Review.

PMID:
22161373
11.

A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.

Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK.

Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14.

PMID:
23672818
12.

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25.

PMID:
22721596
13.

Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.

Schulz KP, Fan J, Bédard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH.

Arch Gen Psychiatry. 2012 Sep;69(9):952-61. doi: 10.1001/archgenpsychiatry.2011.2053.

PMID:
22945622
14.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
15.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
16.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

17.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
18.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ.

Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000.

PMID:
20030423
19.

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K; SUNBEAM Study Group.

Curr Med Res Opin. 2007 Feb;23(2):379-94.

PMID:
17288692
20.

Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.

Chan E, Fogler JM, Hammerness PG.

JAMA. 2016 May 10;315(18):1997-2008. doi: 10.1001/jama.2016.5453. Review.

PMID:
27163988

Supplemental Content

Support Center